지방간에 대한 백두구 에틸아세테이트 추출물의 억제 효과 및 기전 연구
Study of the Suppressive Effect and Its Mechanism of Amomum Cardamomum L. on Free Fatty Acid-induced Liver Steatosis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Through this study, the authors investigated the anti-steatosis effects of the Amomum cardamomum ethyl acetate fraction in free fatty acids (FFAs)-induced human hepatocellular carcinoma HepG2 cells. The ethyl acetate fraction of Amomum cardamomum (ACEA) was extracted with 70% ethanol and then the extract was evaporated using a rotary evaporator prior to sequential fractionation. Human hepatocellular carcinoma were treated with different concentrations of ACEA in the presence and absence of FFAs. To demonstrate the reactive oxygen species (ROS) scavenging activity, DCFDA level was analyzed by using in vitro assay system. Cell viability, lipid accumulation, intracellular triglycerides, malondialdehyde (MDA), liver steatosis related signaling molecules and inflammatory cytokines such as interleukin (IL)-6, 8, tumor necrosis factor-alpha (TNF-α) were also investigated. As results, ACEA inhibited the FFAs-induced ROS, lipid accumulation, intracellular triglycerides, and MDA in a dose dependent manner. Treatment of human hepatocellular cells with ACEA induced the phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK) and carnitine palmitoyltransferase I (CPT1) expression using western blot analysis. ACEA also potently suppressed the FFAs-induced inflammatory cytokines including IL-6, IL-8 and TNF-α. These results suggest that the ethyl acetate fraction of Amomum cardamoum extract own inhibitory effects of liver steatosis by inhibiting ROS, lipid accumulation, intracellular triglycerides, MDA through AMPK signaling and anti-inflammatory actions.
Abstract
Through this study, the authors investigated the anti-steatosis effects of the Amomum cardamomum ethyl acetate fraction in free fatty acids (FFAs)-induced human hepatocellular carcinoma HepG2 cells. The ethyl acetate fraction of Amomum cardamomum (ACEA) was extracted with 70% ethanol and then the extract was evaporated using a rotary evaporator prior to sequential fractionation. Human hepatocellular carcinoma were treated with different concentrations of ACEA in the presence and absence of FFAs. To demonstrate the reactive oxygen species (ROS) scavenging activity, DCFDA level was analyzed by using in vitro assay system. Cell viability, lipid accumulation, intracellular triglycerides, malondialdehyde (MDA), liver steatosis related signaling molecules and inflammatory cytokines such as interleukin (IL)-6, 8, tumor necrosis factor-alpha (TNF-α) were also investigated. As results, ACEA inhibited the FFAs-induced ROS, lipid accumulation, intracellular triglycerides, and MDA in a dose dependent manner. Treatment of human hepatocellular cells with ACEA induced the phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK) and carnitine palmitoyltransferase I (CPT1) expression using western blot analysis. ACEA also potently suppressed the FFAs-induced inflammatory cytokines including IL-6, IL-8 and TNF-α. These results suggest that the ethyl acetate fraction of Amomum cardamoum extract own inhibitory effects of liver steatosis by inhibiting ROS, lipid accumulation, intracellular triglycerides, MDA through AMPK signaling and anti-inflammatory actions.
참고문헌 (30)
- Kumar A, "Patients with nonalcoholic fatty liver disease(NAFDL)have higher oxidative stress in comparison to chronic viral hepatitis", J Clin Exp Hepatol, 3, pp.12~18 (2012)
- Li S, "The role of oxidative stress and antioxidants in liver diseases", Int J Mol Sci, 16, pp.26087~26124 (2015)
- Griffith CM, "The role of nutritional therapy in alcoholic liver disease", Alcohol Res Health, 29, pp.296~306 (2006)
- Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
- Marchesini G, "Association of nonalcoholic fatty liver diseases with insulin resistance", Am J Med, 107, pp.450~455 (1999)
- Sato K, "Vitamin E has a beneficial effects on nonalcoholic fatty liver disease : a meta-analysis of randomized controlled trials", Nutrition, 31, pp.323~930 (2015)
- Rouabhia S, "Metformin in the treatment of non-alcoholic fatty liver disease : safety, efficacy and mechanism", Expert Rev Gastroenterol Hepatol, 8, pp.343~349 (2014)
- Pastori D, "The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease", Dig Liver Dis, 47, pp.4~11 (2015)
- Di Minno MN, "Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease", World J Gastroenterol, 18, pp.5839~5847 (2012)
- Heo J., "Translated Dongeuibogam" (1999), Bubinmunwha
- Lee DH, "Detection of anti-inflammatory agents from natural products as inhibitors of cyclooxygenase I and II", Nat Prod Sci, 3, pp.19~28 (1997)
- Murata S, "1, 8-Cineole ameliorates steatosis of pten liver specific KO mice via Akt inactivation", Int J Mol Sci, 16, pp.12051~12063 (2015)
- Viollet B, "Activation of AMP-activated protein kinase in the liver : a new strategy for the management of metabolic hapatic disorders", J Physiol, 574, pp.41~53 (2006)
- Smith BK, "Treatment of nonalcoholic fatty liver disease : role of AMPK", Am J Physiol Endocrinol Metab, 311, pp.730~740 (2016)
- Kohijima M, "SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease", Int J Mol Med, 21, pp.507~511 (2008)
- Thomson DM, "AMP-activated protein kinase control of fat metabolism in skeletal muscle", Acta Physiol, 196, pp.147~154 (2009)
- Tolman KG, "Treatment of non-alcoholic fatty liver disease", Ther Clin Risk Manaq, 3, pp.1153~1163 (2007)
- Braunersreuther V, "Role of cytokines and chemokines in non-alcoholic fatty liver disease", World J Gastroenterol, 18, pp.727~735 (2012)
- Lim DW, "Amomum cardamomum L. ethyl acetate fraction protects against carbon tetrachloride-induced liver injury via an antioxidant mechanism in rats", BMC Complement Altern Med, 16, pp.155~ (2016)
- Lim DW, "Mofied SJH alleviates FFAs-induced hapatic steatosis through leptin signaling pathways", Sci Rep, 7, pp.45425~ (2017)
- Min KJ, "The effects of oxidized low density lipoprotein (oxLDL)-induced heme oxygenase-1 on LPS-induced inflammation in RAW 264.7 macrophage cells", Cell Signal, 24, pp.1215~1221 (2012)
- Bekkering S, "Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes", Arterioscler Thromb Vasc Biol, 34, pp.1731~1738 (2014)
- Beltowski J, "Statins and modulation of oxidative stress", Toxicol Mech Methods, 15, pp.61~92 (2005)
- Leamy AK, "Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease", Prog Lipid Res, 52, pp.165~174 (2013)
- Boots AW, "Health effects of quercetin : from antioxidant to nutraceutical", Eur J Pharmacol, 585, pp.325~337 (2008)
- Sultana B, "Flavonols(kaempeferol, quercetin, myricetin)contents of selected fruits, vegetables and medicinal plants", Food Chem, 108, pp.879~884 (2008)
- Lee KG, "Inhibitory effects of plant-derived flavonoids and phenolic acids on malonaldehyde formation from ethyl arachidonate", J Agric Food Chem, 51, pp.7203~7207 (2003)
- Horton JD, "SREBPs : activators of the complete program of cholesterol and fatty acid synthesis in the liver", J Clin Invest, 109, pp.1125~1131 (2002)
- 김재은, "Tribulus terrestris Suppresses the Lipopolysaccharide-Induced Inflammatory Reaction in RAW264.7 Macrophages through Heme Oxygenase-1 Expressions", 동의생리병리학회지, 28(1), pp.63~68 (2014), 한의병리학회
- Sikora JP, "Proinflammatory cytokine(IL-6, IL-8), cytokine inhibitors(IL-6sR, STNFRII)and anti-inflammatory cytokines(IL-10, IL-13)in the pathogenesis of sepsis in newborns and infants", Arch Immunol Exp, 49, pp.399~404 (2001)